This is an incredible talk with many many highlights.
Rather than list them, I encourage all investors and prospective investors to listen for themselves.
One snippet I will mention was Dr Vinayak Bapat said "the valve functions beautifully and after follow up in April the hemodynamics remain the same...." to which Dr Christopher Meduri replies "that seems very exciting to see how the valve and the patients continue to do after 3 months...."
This is, as far as I know, the first we've heard about how the valve is continuing to do after the one month follow up results.
The message continues to be the same in EVERY single interview/talk I hear with global experts. The DurAVR meets ALL the currently UNMET clinical needs of the patients and practitioners.... those being in general terms, 1) a valve which will last the lifetime of the patients, 2) a valve which will allow for optimal hemodynamics allowing the patient to live a normal life (returning the patient to a pre-diseased state,) and 3) a valve which can easily and precisely be commisurally aligned with the patients own anatomy.
A massive buyout remains on track, and if not, the incumbents can look forward to major revenue loss, major market share loss, when the DurAVR is allowed to be sold commercially.
Either way, it's a win/win for investors and a massive WIN for all future patients who may require a TAVR implant.
AVR Price at posting:
$16.75 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)